Knowledge Content
From the perspective of its core mechanism of action, the molecular design of AOD9604 does not involve erection-related pathways: it promotes fat breakdown (especially stubborn abdominal fat) by activating β3-adrenergic receptors in adipocytes, while inhibiting fat synthesis, without affecting the normal secretion rhythm of growth hormone (GH). It also does not directly act on the smooth muscle relaxation pathways of the corpora cavernosa (such as the NO-cGMP pathway)-the core target of erectile dysfunction drugs like sildenafil. AOD9604 lacks the ability to directly activate or regulate this pathway, and therefore cannot directly achieve the effect of "maintaining an erection."https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-aod9604-2mg.html
Its indirect auxiliary value is mainly reflected in three scenarios, and it requires improvement in physical condition to achieve: First, for men with erectile dysfunction due to high body fat percentage. Clinical data shows that in men with a body fat percentage exceeding 25%, estrogen levels rise due to increased aromatase activity in adipose tissue, thereby inhibiting endogenous testosterone secretion (testosterone is a key hormone for maintaining libido and erectile function). AOD9604, through 8-12 weeks of fat reduction intervention (2-3 mg daily), can reduce body fat percentage by 3%-5%, indirectly lowering estrogen levels and increasing the testosterone/estrogen ratio, creating a hormonal environment for erectile function recovery. However, this effect requires combined with diet control and exercise; its effect is weak when used alone.
Second, for erectile problems caused by poor vascular health. Erectile dysfunction depends on adequate blood flow to the corpora cavernosa of the penis, while high blood lipids and arteriosclerosis increase blood flow resistance. While AOD9604 reduces fat, it can indirectly improve vascular elasticity and reduce blood flow obstruction by improving insulin sensitivity (lowering fasting blood glucose and triglyceride levels). This provides a slight auxiliary improvement for vascular erectile dysfunction, but it cannot replace the core efficacy of lipid-lowering drugs or vasodilators.
Thirdly, it addresses metabolic disorders accompanied by insufficient energy and psychogenic erectile problems. Some men experience difficulty maintaining an erection due to metabolic imbalances leading to fatigue and anxiety. AOD9604, by regulating metabolism and increasing energy levels, can alleviate fatigue-induced erectile dysfunction and lack of concentration, indirectly improving psychogenic erectile problems. However, it has no auxiliary effect on organic lesions (such as nerve damage or cavernous body fibrosis).
Three key boundaries need to be clarified: First, AOD9604 has no direct effect on enhancing erection and cannot replace dedicated medications such as sildenafil and tadalafil. Patients with erectile dysfunction (ED) should prioritize treatment targeting the underlying cause. Second, its indirect effects are highly individualized; individuals with normal body fat percentages and healthy blood vessels will not experience any erection-related improvement after use. Third, its core value remains focused on fat reduction and muscle repair; its auxiliary effects related to erection are "incidental improvements" and require long-term use to become apparent, and should not be used as a primary goal.
Overall, AOD9604 is not an "erectile maintenance drug." Its impact on erection is an indirect result of metabolic
improvements and is subject to strict limitations. It should be viewed rationally in conjunction with individual physical conditions and should not be used as a solution for erectile dysfunction.
